Kodiak Sciences Inc. (NASDAQ:KOD) Receives Average Recommendation of “Reduce” from Analysts

Kodiak Sciences Inc. (NASDAQ:KODGet Free Report) has been given a consensus recommendation of “Reduce” by the seven research firms that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $5.50.

KOD has been the topic of several recent research reports. Barclays lifted their target price on shares of Kodiak Sciences from $2.00 to $3.00 and gave the stock an “underweight” rating in a research note on Monday, April 1st. UBS Group lifted their target price on shares of Kodiak Sciences from $3.00 to $5.00 and gave the stock a “neutral” rating in a research note on Thursday, April 4th.

Get Our Latest Report on KOD

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC boosted its position in shares of Kodiak Sciences by 253.6% during the 3rd quarter. Acadian Asset Management LLC now owns 1,636,621 shares of the company’s stock valued at $2,945,000 after acquiring an additional 1,173,832 shares during the last quarter. Silverarc Capital Management LLC acquired a new position in Kodiak Sciences in the third quarter valued at about $2,006,000. JGP Global Gestao de Recursos Ltda. acquired a new position in Kodiak Sciences in the fourth quarter valued at about $46,000. Marquette Asset Management LLC lifted its position in Kodiak Sciences by 58.5% in the fourth quarter. Marquette Asset Management LLC now owns 47,944 shares of the company’s stock valued at $146,000 after buying an additional 17,686 shares during the last quarter. Finally, Barclays PLC lifted its position in Kodiak Sciences by 78.3% in the third quarter. Barclays PLC now owns 63,384 shares of the company’s stock valued at $114,000 after buying an additional 27,843 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Kodiak Sciences Stock Performance

Shares of NASDAQ KOD opened at $2.61 on Friday. The firm has a market cap of $137.10 million, a PE ratio of -0.59 and a beta of 2.43. The firm has a fifty day moving average of $3.38 and a 200 day moving average of $4.04. Kodiak Sciences has a one year low of $1.37 and a one year high of $9.00.

Kodiak Sciences (NASDAQ:KODGet Free Report) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.27. On average, equities analysts predict that Kodiak Sciences will post -3.55 EPS for the current fiscal year.

About Kodiak Sciences

(Get Free Report

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

See Also

Analyst Recommendations for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.